Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
» DXR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

DXR Guru Trades in Q2 2013

Jim Simons 47,500 sh (-1.04%)
» More
Q3 2013

DXR Guru Trades in Q3 2013

Jim Simons 47,700 sh (+0.42%)
» More
Q4 2013

DXR Guru Trades in Q4 2013

Jim Simons 47,400 sh (-0.63%)
» More
Q1 2014

DXR Guru Trades in Q1 2014

Jim Simons 47,100 sh (-0.63%)
» More
» Details

Insider Trades

Latest Guru Trades with DXR



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.70
DXR's Dividend Yield is ranked lower than
74% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. DXR: 0.70 )
DXR' s 10-Year Dividend Yield Range
Min: 0   Max: 0
Current: 0.7

Yield on cost (5-Year) 0.70
DXR's Yield on cost (5-Year) is ranked lower than
119% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.47 vs. DXR: 0.70 )
DXR' s 10-Year Yield on cost (5-Year) Range
Min: 0   Max: 0
Current: 0.7

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Daxor Corporation was originally incorporated in New York State as Iatric Corporation in May 1971for cryobanking services and continues these services through its wholly-owned subsidiary, Scientific Medical Systems. In October 1971, the name Iatric Corporation was changed to Idant Corporation. In May 1973, the name Idant Corporation was changed to Daxor Corporation. It is a medical device manufacturing Company, which offers additional biotech services, such as cryobanking, through its wholly owned subsidiary Scientific Medical Systems Corp. The main focus of the Company has been the development and marketing of an instrument that rapidly and accurately measures human blood volume. This instrument is used in conjunction with a single use diagnostic injection and collection kit that the Company also sells to its customers. The Company's main focus has been on the development of the BVA-100(r) Blood Volume Analyzer, an instrument that rapidly and accurately measures human blood volume. The instrument is used in conjunction with Volumex(r), a single-use radiopharmaceutical diagnostic injection and collection kit. The BVA-100 has also been used to aid in the diagnosis and treatment of polycythemia, hypertension, anemia, chronic fatigue, and to aid in presurgical evaluation. Additional possible uses include management of kidney dialysis, ultrafiltration, and blood optimization for elective surgery. The Company's marketing of the blood volume analyzer could be divided roughly into three phases: initial beta testing at local facilities, late-stage beta testing at nationally recognized institutions - with an emphasis on developing studies for publication, and marketing of the instrument for clinical use. During late-stage beta testing and the marketing phase, the instrument continued to experience a number of major technical improvements and alternations. It competes for customers based on a variety of factors, including reputation, customer service, performance, expertise, price and scope of service offerings.
» More Articles for DXR

Headlines

Articles On GuruFocus.com
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
Weekly 3-Year Low Stocks: PBR, NJ, DWA, DXR Feb 10 2013 
High Yields In Healthcare Sector May 26 2011 
Daxor Corp Reports Operating Results (10-Q) Nov 12 2010 
Daxor Corp Reports Operating Results (10-Q) Aug 13 2010 
Daxor Corp Reports Operating Results (10-Q) May 11 2010 
Daxor Corp Reports Operating Results (10-Q) Nov 12 2009 
Daxor Corp Reports Operating Results (10-Q) Aug 13 2009 
Daxor Corp Reports Operating Results (10-Q) May 12 2009 

More From Other Websites
Daxor to Explore Possible Partnership or Partial Sale of the Company Jun 19 2014
Heart Failure Study From the Mayo Clinic Utilizing Daxor's BVA-100 Blood Volume Analyzer Published... May 30 2014
Daxor Corporation's Idant Laboratories Subsidiary Earns American Association of Blood Banks (AABB)... Apr 30 2014
Dr. Feldschuh, CEO of Daxor, Returned to Work After Fracturing a Hip, Speaks About Extensive Blood... Apr 10 2014
A Little-Known Device That Can Save Your Life Mar 12 2014
Daxor Corporation Announces Filing of Form N-CSR for December 31, 2013 Feb 28 2014
Daxor Corporation Announces Filing of Form N-CSR for December 31, 2013 Feb 28 2014
Daxor Corporation Announces Dr. Joseph Feldschuh, President and CEO, Sustained a Fractured Hip, Had... Feb 11 2014
Daxor Corporation Announces Dr. Joseph Feldschuh, President and CEO, Sustained a Fractured Hip, Had... Feb 11 2014
Daxor Announces a Research Study That Proves Micro Samples are Feasible for Accurate Blood Volume... Jan 15 2014
Daxor Announces a Research Study That Proves Micro Samples Are Feasible for Accurate Blood Volume... Jan 15 2014
/ CORRECTION - Classic Textbook on Critical Care, the ICU book by Paul Marino, M.D., PhD.,... Jan 07 2014
Classic Textbook on Critical Care, the ICU book by Paul Marino, M.D., PhD., Recommends Direct... Jan 07 2014
Daxor Corporation Announces Payment of a Dividend Nov 15 2013
Daxor Corporation Announces Payment of a Dividend Nov 15 2013
Daxor Corporation Announces a Study on the Significant Diagnostic Benefits to Congestive Heart... Oct 25 2013
Daxor Corporation Announces Results of Blood Volume Measurement Study at the Mayo Clinic Presented... Oct 08 2013
Daxor Corporation Announces Filing of Form N-CSR for June 30, 2013 Aug 23 2013
Daxor Corporation Announces Receipt of Blood Banking Contract From Prestigious Law Firm Stroock &... Aug 07 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide